You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Despite its relatively low profile since it kicked off its third phase last spring, the Broad Institute's RNAi Consortium is proceeding apace, although its mission has expanded beyond its initial focus of just RNAi.
The publication comes as the RNAi Consortium looks to expand its work beyond gene silencing to include gain-of-function research.
While the exact goals of the so-called TRC3 have yet to be defined, the initiative expects that these will include the expansion of its scope to include reagents targeting non-coding RNAs.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.